ClinicalTrials.Veeva

Menu
U

Urological Research Network Corp | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Vibegron
TAR-200
Apalutamide
Gemcitabine
Erdafitinib
Fesoterodine
Infigratinib
Cisplatin
Sasanlimab
Androgen

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 16 total trials

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Active, not recruiting
Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for partic...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: Erdafitinib
Drug: Investigator Choice (Mitomycin C)

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder canc...

Active, not recruiting
Non-muscle Invasive Bladder Cancer
Drug: Bacillus Calmette-Guerin
Drug: PF-06801591

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Enrolling
Bladder Cancer
Biological: Cetrelimab
Drug: TAR-200

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: Cisplatin
Radiation: Hypo-fractioned radiation therapy
Locations recently updated

Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the i...

Enrolling
High-risk Non-muscle Invasive Bladder Cancer
Biological: Pembrolizumab
Biological: BCG

A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects...

Active, not recruiting
Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms
Device: ProVee Urethral Expander System
Procedure: Urethral Access Sheath

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Pfizer logo
U
B
D
G
Janssen (J&J Innovative Medicine) logo
L
Merck Sharp & Dohme (MSD) logo
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems